Circulating microbiome in patients with portal hypertension-Reference-Cited by-同舟云学术

Circulating microbiome in patients with portal hypertension

Published:2022-02-07 Issue:1 Volume:14 Page:
ISSN:1949-0976
Container-title:Gut Microbes
language:en
Short-container-title:Gut Microbes

Author:

Gedgaudas Rolandas¹²,Bajaj Jasmohan S³^ORCID,Skieceviciene Jurgita²,Varkalaite Greta²,Jurkeviciute Gabija²,Gelman Sigita¹²,Valantiene Irena¹²,Zykus Romanas¹²,Pranculis Andrius⁴,Bang Corinna⁵,Franke Andre⁵^ORCID,Schramm Christoph⁶⁷,Kupcinskas Juozas¹²^ORCID

Affiliation:

1. Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania

2. Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania

3. Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA

4. Department of Radiology, Lithuanian University of Health Sciences, Kaunas, Lithuania

5. Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany

6. Ist Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

7. Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Funder

Research Council of Lithuania

Publisher

Informa UK Limited

Subject

Infectious Diseases,Microbiology (medical),Gastroenterology,Microbiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/19490976.2022.2029674

Reference65 articles.

1. Individualized care for portal hypertension: Not quite yet

2. Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis

3. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

4. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis

5. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis;Journal of Infection and Public Health;2024-10

2. Bacteriocin KvarM versus Antibiotics: evaluation of antimicrobial activity in a mouse model of intestinal colonization by Klebsiella pneumoniae;2024-09-05

3. Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation;Journal of Gastroenterology;2024-07-19

4. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease;Scientific Reports;2024-07-12

5. Blood Microbiota and Its Products: Mechanisms of Interference with Host Cells and Clinical Outcomes;Hematology Reports;2024-07-06